5 Small Company Stocks You Should Own Now for the Next Decade

3. Fate Therapeutics, Inc. (NASDAQ:FATE)

Number of Hedge Fund Holders: 31

Fate Therapeutics, Inc. (NASDAQ:FATE) is a La Jolla, California-based clinical-stage biotech company focused on developing first-in-class cellular immunotherapies for cancer patients.

Fate Therapeutics, Inc. (NASDAQ:FATE) is a part of Cathie Wood’s ARK Investment portfolio. The hedge fund acquired 628,000 shares of Fate Therapeutics, Inc. (NASDAQ:FATE) on August 11. As of June 30, the hedge fund was the second biggest shareholder in the company, with over 11.4 million shares.

Matthew Biegler at Oppenheimer has given Fate Therapeutics, Inc. (NASDAQ:FATE) stock an Outperform rating with a target price of $90 on August 4. The analyst is waiting for the outcome of the meeting with the FDA as it could prompt the company to take FT596 or FT 516 into a Registrational Trial next year. Analysts see Fate Therapeutics, Inc. (NASDAQ:FATE) as having important drugs in its pipeline that could help the company observe significant growth in the next few years.